Interleukin-27 Ameliorates Atherosclerosis in ApoE-/- Mice through Regulatory T Cell Augmentation and Dendritic Cell Tolerance
Atherosclerosis, which is characterized by chronic inflammation in the arterial wall, is driven by immune cells and cytokines. Recent evidence indicated that interleukin (IL)-27 showed pleiotropic properties in immune diseases. However, precise mechanisms of IL-27, especially in atherosclerosis rema...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2022/2054879 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849467056763699200 |
|---|---|
| author | Wenbin Xu Ruirui Zhu Zhengfeng Zhu Kunwu Yu Yue Wang Yan Ding Jian Yu Hongxia Tang Qiutang Zeng Yucheng Zhong |
| author_facet | Wenbin Xu Ruirui Zhu Zhengfeng Zhu Kunwu Yu Yue Wang Yan Ding Jian Yu Hongxia Tang Qiutang Zeng Yucheng Zhong |
| author_sort | Wenbin Xu |
| collection | DOAJ |
| description | Atherosclerosis, which is characterized by chronic inflammation in the arterial wall, is driven by immune cells and cytokines. Recent evidence indicated that interleukin (IL)-27 showed pleiotropic properties in immune diseases. However, precise mechanisms of IL-27, especially in atherosclerosis remains unknown. In our research, we examined the influence of the administration of IL-27 and an anti-IL-27p28 antibody (anti-IL-27p28-Ab) on both the initiation and the progression of atherosclerosis. In the groups (both the initiation and the progression) receiving recombinant IL-27 administration, the formation of atherosclerotic plaques was suspended, and the percentage of regulatory T cells (LAP+ or Foxp3+) in the spleen and peripheral blood was increased. Meanwhile, the number of T helper 1 (Th1) and T helper 17 (Th17) cells was decreased. In the peripheral blood plasma, TGF-β and IL-10 expression were increased, while the levels of IFN-γ and IL-17 were reduced. As for lesions, the mRNA expression of Foxp3, TGF-β, and IL-10 was increased, while that of IFN-γ and IL-17 was reduced. In the anti-IL-27p28 antibody groups, we obtained opposite results. We also observed that DCs treated with IL-27 display a tolerogenic phenotype and that IL-27–treated tolerogenic DCs (tDCs) are likely to play a protective role during atherosclerosis. Our study indicates that IL-27 or adoptive transfer of IL-27 loaded tDCs may be a new therapeutic approach in atherosclerosis. |
| format | Article |
| id | doaj-art-5fb63563305046f58de74e6d33f23c8a |
| institution | Kabale University |
| issn | 1466-1861 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-5fb63563305046f58de74e6d33f23c8a2025-08-20T03:34:53ZengWileyMediators of Inflammation1466-18612022-01-01202210.1155/2022/2054879Interleukin-27 Ameliorates Atherosclerosis in ApoE-/- Mice through Regulatory T Cell Augmentation and Dendritic Cell ToleranceWenbin Xu0Ruirui Zhu1Zhengfeng Zhu2Kunwu Yu3Yue Wang4Yan Ding5Jian Yu6Hongxia Tang7Qiutang Zeng8Yucheng Zhong9Department of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of Infectious and Immunological DiseasesDepartment of CardiologyDepartment of CardiologyAtherosclerosis, which is characterized by chronic inflammation in the arterial wall, is driven by immune cells and cytokines. Recent evidence indicated that interleukin (IL)-27 showed pleiotropic properties in immune diseases. However, precise mechanisms of IL-27, especially in atherosclerosis remains unknown. In our research, we examined the influence of the administration of IL-27 and an anti-IL-27p28 antibody (anti-IL-27p28-Ab) on both the initiation and the progression of atherosclerosis. In the groups (both the initiation and the progression) receiving recombinant IL-27 administration, the formation of atherosclerotic plaques was suspended, and the percentage of regulatory T cells (LAP+ or Foxp3+) in the spleen and peripheral blood was increased. Meanwhile, the number of T helper 1 (Th1) and T helper 17 (Th17) cells was decreased. In the peripheral blood plasma, TGF-β and IL-10 expression were increased, while the levels of IFN-γ and IL-17 were reduced. As for lesions, the mRNA expression of Foxp3, TGF-β, and IL-10 was increased, while that of IFN-γ and IL-17 was reduced. In the anti-IL-27p28 antibody groups, we obtained opposite results. We also observed that DCs treated with IL-27 display a tolerogenic phenotype and that IL-27–treated tolerogenic DCs (tDCs) are likely to play a protective role during atherosclerosis. Our study indicates that IL-27 or adoptive transfer of IL-27 loaded tDCs may be a new therapeutic approach in atherosclerosis.http://dx.doi.org/10.1155/2022/2054879 |
| spellingShingle | Wenbin Xu Ruirui Zhu Zhengfeng Zhu Kunwu Yu Yue Wang Yan Ding Jian Yu Hongxia Tang Qiutang Zeng Yucheng Zhong Interleukin-27 Ameliorates Atherosclerosis in ApoE-/- Mice through Regulatory T Cell Augmentation and Dendritic Cell Tolerance Mediators of Inflammation |
| title | Interleukin-27 Ameliorates Atherosclerosis in ApoE-/- Mice through Regulatory T Cell Augmentation and Dendritic Cell Tolerance |
| title_full | Interleukin-27 Ameliorates Atherosclerosis in ApoE-/- Mice through Regulatory T Cell Augmentation and Dendritic Cell Tolerance |
| title_fullStr | Interleukin-27 Ameliorates Atherosclerosis in ApoE-/- Mice through Regulatory T Cell Augmentation and Dendritic Cell Tolerance |
| title_full_unstemmed | Interleukin-27 Ameliorates Atherosclerosis in ApoE-/- Mice through Regulatory T Cell Augmentation and Dendritic Cell Tolerance |
| title_short | Interleukin-27 Ameliorates Atherosclerosis in ApoE-/- Mice through Regulatory T Cell Augmentation and Dendritic Cell Tolerance |
| title_sort | interleukin 27 ameliorates atherosclerosis in apoe mice through regulatory t cell augmentation and dendritic cell tolerance |
| url | http://dx.doi.org/10.1155/2022/2054879 |
| work_keys_str_mv | AT wenbinxu interleukin27amelioratesatherosclerosisinapoemicethroughregulatorytcellaugmentationanddendriticcelltolerance AT ruiruizhu interleukin27amelioratesatherosclerosisinapoemicethroughregulatorytcellaugmentationanddendriticcelltolerance AT zhengfengzhu interleukin27amelioratesatherosclerosisinapoemicethroughregulatorytcellaugmentationanddendriticcelltolerance AT kunwuyu interleukin27amelioratesatherosclerosisinapoemicethroughregulatorytcellaugmentationanddendriticcelltolerance AT yuewang interleukin27amelioratesatherosclerosisinapoemicethroughregulatorytcellaugmentationanddendriticcelltolerance AT yanding interleukin27amelioratesatherosclerosisinapoemicethroughregulatorytcellaugmentationanddendriticcelltolerance AT jianyu interleukin27amelioratesatherosclerosisinapoemicethroughregulatorytcellaugmentationanddendriticcelltolerance AT hongxiatang interleukin27amelioratesatherosclerosisinapoemicethroughregulatorytcellaugmentationanddendriticcelltolerance AT qiutangzeng interleukin27amelioratesatherosclerosisinapoemicethroughregulatorytcellaugmentationanddendriticcelltolerance AT yuchengzhong interleukin27amelioratesatherosclerosisinapoemicethroughregulatorytcellaugmentationanddendriticcelltolerance |